References
- SPADA M., PAGLIARDINI S., YASUDA M., TUKEL T., THIAGARAJAN G., SAKURABA H., et al., High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet, 2006. 79(1): p. 31-40.
- MEIKLE P. J., HOPWOOD J. J., CLAGUE A. E. and CAREY W. F., Prevalence of lysosomal storage disorders. Jama, 1999. 281(3): p. 249–54.
- BURLINA A. B., POLO G., SALVIATI L., DURO G., ZIZZO C., DARDIS A., et al., Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J Inherit Metab Dis, 2018. 41(2): p. 209–219.
- ORTIZ A., GERMAIN D. P., DESNICK R. J., POLITEI J., MAUER M., BURLINA A., et al., Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab, 2018. 123(4): p. 416–427.
- MAIER E. M., OSTERRIEDER S., WHYBRA C., RIES M., GAL A., BECK M., et al., Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl, 2006. 95(451): p. 30–8.
- ECHEVARRIA L., BENISTAN K., TOUSSAINT A., DUBOURG O., HAGEGE A. A., ELADARI D., et al., X-chromosome inactivation in female patients with Fabry disease. Clin Genet, 2016. 89(1): p. 44–54.
- WANG R. Y., LELIS A., MIROCHA J. and WILCOX W. R., Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med, 2007. 9(1): p. 34–45.
- BECK M., RAMASWAMI U., HERNBERG-STÅHL E., HUGHES D. A., KAMPMANN C., MEHTA A. B., et al., Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis, 2022. 17(1): p. 238.
- EVANGELISTA Arturo, FLACHSKAMPF Frank, LANCELLOTTI Patrizio, BADANO Luigi, AGUILAR Rio, MONAGHAN Mark, et al., European Association of Echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies. European Journal of Echocardiography, 2008. 9(4): p. 438–448.
- MEHTA A., CLARKE J. T., GIUGLIANI R., ELLIOTT P., LINHART A., BECK M., et al., Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet, 2009. 46(8): p. 548–52.
- MEHTA A., RICCI R., WIDMER U., DEHOUT F., GARCIA DE LORENZO A., KAMPMANN C., et al., Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest, 2004. 34(3): p. 236–42.
- GIUGLIANI Roberto, NIU Dau-Ming, RAMASWAMI Uma, WEST Michael, HUGHES Derralynn, KAMPMANN Christoph, et al., A 15-Year Perspective of the Fabry Outcome Survey. Journal of Inborn Errors of Metabolism and Screening, 2016. 4.
- DEEGAN P. B., BAEHNER A. F., BARBA ROMERO M. A., HUGHES D. A., KAMPMANN C. and BECK M., Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet, 2006. 43(4): p. 347–52.
- LINHART A., KAMPMANN C., ZAMORANO J. L., SUNDER-PLASSMANN G., BECK M., MEHTA A., et al., Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J, 2007. 28(10): p. 1228–35.
- ARENDS M., KÖRVER S., HUGHES D. A., MEHTA A., HOLLAK C. E. M. and BIEGSTRAATEN M., Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. (1573-2665 (Electronic)).
- HANINGER-VACARIU Natalja, ANASTOPOULOS Kyra, AIGNER Christof, SUNDER-PLASSMANN Raute, GATTERER Constantin, PONLEITNER Markus, et al., Pregnancy outcomes of Fabry disease in Austria (PROFABIA)-a retrospective cohort-study. Orphanet Journal of Rare Diseases, 2024. 19(1): p. 165.
- LUKAS J., GIESE A. K., MARKOFF A., GRITTNER U., KOLODNY E., MASCHER H., et al., Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. PLoS Genet, 2013. 9(8): p. e1003632.
- NAJAFIAN B., TØNDEL C., SVARSTAD E., GUBLER M. C., OLIVEIRA J. P. and MAUER M., Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. J Am Soc Nephrol, 2020. 31(4): p. 865–875.
- ROMBACH S. M., DEKKER N., BOUWMAN M. G., LINTHORST G. E., ZWINDERMAN A. H., WIJBURG F. A., et al., Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta, 2010. 1802(9): p. 741–8.
- COATS C. J., PARISI V., RAMOS M., JANAGARAJAN K., O'MAHONY C., DAWNAY A., et al., Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease. Am J Cardiol, 2013. 111(1): p. 111–7.
- SEYDELMANN N., LIU D., KRÄMER J., DRECHSLER C., HU K., NORDBECK P., et al., High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease. J Am Heart Assoc, 2016. 5(6).
- YOUSEF Z., ELLIOTT PM FAU - CECCHI Franco, CECCHI F FAU - ESCOUBET Brigitte, ESCOUBET B FAU - LINHART Ales, LINHART A FAU - MONSERRAT Lorenzo, MONSERRAT L FAU - NAMDAR Mehdi, et al., Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. (1522–9645 (Electronic)).
- SENÉ T., LIDOVE O FAU - SEBBAH Joel, SEBBAH J FAU - DARONDEL Jean-Marc, DARONDEL JM FAU - PICARD Hervé, PICARD H FAU - AARON Laurent, AARON L FAU - FAIN Olivier, et al., Cardiac device implantation in Fabry disease: A retrospective monocentric study. (1536–5964 (Electronic)).
- VIJAPURAPU Ravi, GEBERHIWOT Tarekegn, JOVANOVIC Ana, BAIG Shanat, NORDIN Sabrina, KOZOR Rebecca, et al., Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. Heart, 2019. 105(23): p. 1825–1831.
- KAMPMANN C., WIETHOFF C. M., WHYBRA C., BAEHNER F. A., MENGEL E. and BECK M., Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr, 2008. 97(4): p. 463–9.
- PIERONI M., MOON J. C., ARBUSTINI E., BARRIALES-VILLA R., CAMPOREALE A., VUJKOVAC A. C., et al., Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. (1558–3597 (Electronic)).
- NIEMANN M., HERRMANN S., HU K., BREUNIG F., STROTMANN J., BEER M., et al., Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging, 2011. 4(6): p. 592–601.
- GRAZIANI Francesca, LILLO Rosa, PANAIOLI Elena, SPAGNOLETTI Gionata, PIERONI Maurizio, FERRAZZI Paolo, et al., Evidence of evolution towards left midventricular obstruction in severe Anderson–Fabry cardiomyopathy. ESC Heart Failure, 2021. 8(1): p. 725–728.
- GRAZIANI F., LAURITO M., PIERONI M., PENNESTRI F., LANZA G. A., COLUCCIA V., et al., Right Ventricular Hypertrophy, Systolic Function, and Disease Severity in Anderson-Fabry Disease: An Echocardiographic Study. J Am Soc Echocardiogr, 2017. 30(3): p. 282–291.
- MILITARU S., GINGHINA C., POPESCU B. A., SAFTOIU A., LINHART A. and JURCUT R., Multimodality imaging in Fabry cardiomyopathy: from early diagnosis to therapeutic targets. (2047–2412 (Electronic)).
- DEVA Dp Auid-Orcid X., HANNEMAN K., LI Q., NG M. Y., WASIM S., MOREL C., et al., Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease. (1532–429X (Electronic)).
- THOMPSON R. B., CHOW K FAU - KHAN Aneal, KHAN A FAU - CHAN Alicia, CHAN A FAU - SHANKS Miriam, SHANKS M FAU - PATERSON Ian, PATERSON I FAU - OUDIT Gavin Y., et al., T₁ mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. (1942–0080 (Electronic)).
- ORTIZ A., GERMAIN D. P., DESNICK R. J., POLITEI J., MAUER M., BURLINA A., et al., Fabry disease revisited: Management and treatment recommendations for adult patients. (1096–7206 (Electronic)).
- WILCOX W. R., OLIVEIRA JP FAU - HOPKIN Robert J., HOPKIN RJ FAU - ORTIZ Alberto, ORTIZ A FAU - BANIKAZEMI Maryam, BANIKAZEMI M FAU - FELDT-RASMUSSEN Ulla, FELDT-RASMUSSEN U FAU - SIMS Katherine, et al., Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. (1096–7206 (Electronic)).
- BARBA-ROMERO MÁ and PINTOS-MORELL G., Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey. Int J Mol Sci, 2016. 17(12).
- LENDERS M., HENNERMANN J. B., KURSCHAT C., ROLFS A., CANAAN-KÜHL S., SOMMER C., et al., Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease. Orphanet J Rare Dis, 2016. 11(1): p. 88.
- WALDEK Stephen, PATEL Manesh R, BANIKAZEMI Maryam, LEMAY Roberta and LEE Philip, Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genetics in Medicine, 2009. 11(11): p. 790–796.